Loading...
•
Jun 30, 2020
Eagle Q2 2020 Earnings Report
Reported a net loss and an adjusted non-GAAP net income, advanced pipeline of oncology and critical care products, and achieved legal wins for BENDEKA.
Key Takeaways
Eagle Pharmaceuticals reported Q2 2020 revenue of $41.9 million, a net loss of $0.3 million, and an adjusted non-GAAP net income of $8.0 million. The company is advancing its pipeline of oncology and critical care products and anticipates the launch of vasopressin.
Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share.
Anticipate launch of vasopressin, maintaining 180-day market exclusivity.
CMS establishes unique J-code for PEMFEXY™ (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial.
Received positive additional data for the Company’s fulvestrant product candidate, EA-114, for HR-positive advanced breast cancer.
Eagle
Eagle
Forward Guidance
The guidance represents forward-looking information, and actual results may vary.